Dermata Therapeutics (DRMA) Stock Price, News & Analysis

Company Overview

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Key Stats

• Today's Range: $5.30 to $5.61
• 50-Day Range: $5.33 to $7.30
• 52-Week Range: $5.09 to $24.90
• Volume: 13,065 shs
• Average Volume: 27,894 shs
• Market Capitalization: $3.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Dermata Therapeutics Stock Analysis - MarketRank™

Dermata Therapeutics scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dermata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Dermata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dermata Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dermata Therapeutics is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dermata Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.78% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently decreased by 96.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dermata Therapeutics does not currently pay a dividend.

Dividend Growth

Dermata Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.78% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently decreased by 96.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

News Sentiment

Dermata Therapeutics has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Dermata Therapeutics this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for DRMA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.50% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.67% of the stock of Dermata Therapeutics is held by institutions.

DRMA Stock Analysis - Frequently Asked Questions

How have DRMA shares performed this year?

Dermata Therapeutics' stock was trading at $13.50 at the beginning of the year. Since then, DRMA stock has decreased by 59.4% and is now trading at $5.48.

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its quarterly earnings results on Wednesday, August, 13th. The company reported ($1.66) earnings per share for the quarter, beating the consensus estimate of ($2.90) by $1.24.

When did Dermata Therapeutics' stock split?

Dermata Therapeutics's stock reverse split on Thursday, May 16th 2024.The 1-15 reverse split was announced on Thursday, May 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Dermata Therapeutics IPO?

Dermata Therapeutics (DRMA) raised $18 million in an IPO on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

Who are Dermata Therapeutics' major shareholders?

Top institutional investors of Dermata Therapeutics include Armistice Capital LLC (50.50%).

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dermata Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dermata Therapeutics investors own include BIOLASE (BIOL), CNS Pharmaceuticals (CNSP), Esports Entertainment Group (GMBL), Jiuzi (JZXN), Kiora Pharmaceuticals (KPRX), ENDRA Life Sciences (NDRA) and Sonnet BioTherapeutics (SONN).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 8/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRMA
• CIK: 1853816
• Web: www.dermatarx.com
• Phone: 858-800-2543
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dermata Therapeutics: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +82.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($16.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -214.98%
• Return on Assets: -153.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.47
• Quick Ratio: 6.47

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.24 per share
• Price / Book: 0.67

Miscellaneous

• Outstanding Shares: 680,000
• Free Float: 556,000
• Market Cap: $3.73 million
• Optionable: Not Optionable
• Beta: 0.56